Search Results
482 results found-
Should you get both vaccinations? Yes, says an infectious disease doctor with the U.S. National Foundation for Infectious Diseases.
https://www.csl.com/we-are-csl/vita-original-stories/2021/protecting-yourself-from-covid-19-and-influenza -
CSL presents the World of Promise podcast series, focused on the promise of biotechnology.
https://www.csl.com/we-are-csl/csl-podcasts -
3 Pandemic flu occurs when a novel strain emerges that infects people, spreads easily from person-to-person, and to which most people do not have immunity.
https://newsroom.csl.com/2023-09-18-CSL-Seqirus-Shares-Data-Demonstrating-the-Potential-for-Influenza-Vaccination-to-Reduce-the-Burden-on-Healthcare-Resources -
The agreement grants access to Arcturus Therapeutics' late-stage self-amplifying mRNA (sa-mRNA) vaccine platform technology, which recently reported results from a large COVID-19 Phase III vaccine efficacy study, meeting its primary and secondary endpoints of prevention of infection and severe disease with a favorable safety and tolerability profile.
https://newsroom.csl.com/2022-12-12-CSL-Announces-Closing-of-Global-Collaboration-and-Licensing-Agreement-with-Arcturus-Therapeutics -
6,7 Pandemic flu occurs when a novel strain emerges that infects people, spreads easily from person-to-person, and to which most people do not have immunity.
https://newsroom.csl.com/2023-09-15-CSL-Seqirus-to-Present-at-9th-ESWI-Conference-on-the-Burden-of-Influenza-and-Impact-of-Vaccination-on-Public-Health -
It has developed a COVID-19 vaccine candidate and has recently reported results from a large Phase III vaccine efficacy study, meeting its primary and secondary endpoints of prevention of infection and severe disease with a favorable safety and tolerability profile.
https://newsroom.csl.com/2022-11-01-CSL-Enters-Licensing-Agreement-with-Arcturus-Therapeutics-for-Next-Generation-mRNA-Vaccine-Technology -
Alpha 1 Antitrypsin (AAT) Deficiency is a genetic condition which can affect the lungs and liver. Learn more about this condition and what it means for patients.
https://www.csl.com/patients-public-health/rare-and-serious-diseases/alpha-1-antitrypsin-deficiency -
As a clinician, I look forward to being able to provide a new treatment option that may help patients treated with HEMGENIX become free from the regular infusion schedule that many people living with hemophilia B rely on to protect them from the debilitating effects of the condition.
https://newsroom.csl.com/2022-11-22-U-S-Food-and-Drug-Administration-approves-CSLs-HEMGENIX-R-etranacogene-dezaparvovec-drlb-,-the-first-gene-therapy-for-hemophilia-B -
From April 24-30, public health officials raise awareness about the protection vaccines provide and their potential to improve global health. This year, the World Health Organization (WHO) celebrates 50 years of its Expanded Programme on Immunization.
https://www.csl.com/we-are-csl/vita-original-stories/2024/world-immunization-week-2024 -
CSL Seqirus has started shipping influenza vaccines to health care providers in the United States, helping them get prepared for the upcoming flu season.
https://www.csl.com/we-are-csl/vita-original-stories/2023/now-shipping-flu-vaccines